Sinogene Biotechnology

Sinogene Biotechnology is a Chinese biotechnology company focused on animal cloning technology, with particular visibility in companion-animal cloning and experimental work involving endangered species. The company began offering dog-cloning services in 2017 and expanded into cat cloning in 2019. Its consumer-facing model includes the collection and preservation of cells from living pets, allowing customers to retain biological material that could potentially be used for cloning after an animal dies. According to the available reference material, cloned animals are delivered to customers three months after birth, with fees beginning at approximately US$55,000; the timing and pricing should be understood as reported service information rather than a complete or current price list. Sinogene’s best-known research milestone came in 2022, when it reported the first successful cloning of a wild Arctic wolf. The project used cells from a wild female Arctic wolf, oocytes from a female dog, and a beagle as the surrogate. The company transferred 85 embryos into seven beagles, producing an Arctic wolf. The result attracted attention because it demonstrated a cross-species reproductive approach involving an endangered or conservation-sensitive animal and a domestic surrogate species. The work also placed Sinogene within wider debates about whether cloning can complement, but not replace, habitat protection, population management, genetic diversity programs, and conventional conservation breeding. In the same year, Sinogene partnered with Beijing Wildlife Park on work intended to improve breeding of endangered animals and develop methods for their protection. This partnership connected the company’s commercial cloning capabilities with conservation-oriented applications, although the available material does not establish the scale, duration, or measurable outcomes of the collaboration. In 2023, Sinogene began horse-cloning activities. It reported cloning a male horse using skin cells from a horse born in 1995, extending its work beyond dogs, cats, and conservation-related projects. The company’s positioning combines reproductive biotechnology, genetic-material preservation, companion-animal services, and applied conservation research. Its services are technologically specialized and premium-priced, and its public profile is driven by unusual animal-cloning achievements rather than by a broad portfolio of conventional pharmaceutical, diagnostic, or agricultural biotechnology products. Information available for this dossier does not establish Sinogene’s corporate ownership, exact headquarters, executive leadership, legal structure, financial performance, listing status, or geographic distribution of customers. Those fields are therefore left unspecified.

Sinogene Biotechnology is a Chinese biotechnology company whose documented activities center on animal cloning. Rather than operating primarily as a pharmaceutical or medical-products company, it has developed a public identity around reproductive biotechnology, companion-animal cloning, genetic-material preservation, and experimental conservation applications. The company began offering dog-cloning services in 2017. This placed it in a highly specialized and ethically debated commercial market in which customers seek genetic replicas of deceased or aging companion animals. Sinogene later expanded its consumer-facing work to cats, introducing cat-cloning services in 2019. Its service model also includes the harvesting and preservation of cells from living pets. The purpose of this preservation is to maintain biological material that could potentially be used in a future cloning procedure after the original animal dies. The available reference material states that customers receive cloned animals three months after birth and that fees start at approximately US$55,000, although no detailed current pricing schedule is available here. Sinogene’s most prominent scientific milestone occurred in 2022. The company reported that it had successfully cloned a wild Arctic wolf, describing the achievement as the first of its kind. The procedure used donor cells from a wild female Arctic wolf, oocytes from a female dog, and a beagle as the surrogate. Sinogene transferred 85 embryos into seven beagles, and one Arctic wolf was born. The project is notable for its use of reproductive material from different canid species and for its potential relevance to the conservation of genetically valuable or endangered animals. At the same time, a single cloned animal does not by itself resolve broader conservation challenges such as habitat loss, limited population diversity, disease, or the need for sustainable breeding programs. Also in 2022, Sinogene partnered with Beijing Wildlife Park. The stated purpose of the collaboration was to improve breeding methods for endangered animals and develop better ways to protect them. This initiative broadened the company’s public narrative from pet cloning toward conservation biotechnology. The available sources do not provide enough information to assess the partnership’s duration, specific species portfolio, funding, or results. In 2023, Sinogene began horse-cloning work. It reported the cloning of a male horse using skin cells from a horse born in 1995. This represented an expansion of the company’s documented work into equine cloning and demonstrated an effort to apply its techniques across multiple domestic and conservation-relevant animal species. Sinogene’s history therefore consists of three overlapping strands: commercial cloning services for dogs and cats; biological-material preservation intended to support future cloning; and research or partnerships involving larger animals and endangered-species conservation. Its public profile is shaped by technically unusual achievements and high-value services. The available material does not establish the company’s founding date, founder, corporate parent, ownership, executive team, financial results, exact headquarters, or international market footprint.

• 2023

  Horse cloning begins

  [1]Sinogene Biotechnologyen.wikipedia.org

  Sinogene began horse-cloning work and reported cloning a male horse from skin cells taken from a horse born in 1995.

• 2022

  Wild Arctic wolf cloned

  [1]Sinogene Biotechnologyen.wikipedia.org

  Sinogene reported the first successful cloning of a wild Arctic wolf using cells from a wild female wolf, dog oocytes, and a beagle surrogate.

• 2022

  Beijing Wildlife Park collaboration

  [1]Sinogene Biotechnologyen.wikipedia.org

  Sinogene partnered with Beijing Wildlife Park on endangered-animal breeding and protection initiatives.

• 2019

  Cat-cloning services introduced

  [1]Sinogene Biotechnologyen.wikipedia.org

  The company expanded its animal-cloning services to cats.

• 2017

  Dog-cloning services begin

  [1]Sinogene Biotechnologyen.wikipedia.org

  Sinogene began offering commercial dog-cloning services.

A specialized animal-biotechnology company positioned at the intersection of commercial pet cloning, genetic preservation, reproductive science, and conservation-oriented cloning research.

• Companion-animal biotechnology · 2017

  Dog cloning services

  Sinogene has offered dog-cloning services since 2017. The service is intended to produce a genetic copy of a customer’s dog through somatic-cell cloning and related reproductive procedures. The available material does not describe the full clinical workflow, eligibility requirements, success rates, or current pricing beyond reporting starting fees for the company’s cloning services.

• Companion-animal biotechnology · 2019

  Cat cloning services

  Introduced in 2019, Sinogene’s cat-cloning offering extends its companion-animal business beyond dogs. The service depends on the preservation and use of suitable genetic material and on assisted-reproduction procedures. Available reference material does not provide a detailed breakdown of the service package, delivery process, or current commercial availability.

• Genetic preservation

  Pet-cell preservation

  Sinogene allows clients to collect and preserve cells from living pets. The preserved material may be used in a future cloning process after the animal dies, subject to the technical feasibility of the cells and the availability of a suitable cloning program. This offering separates the timing of biological-material collection from the later decision to pursue cloning.

• Conservation biotechnology · 2022

  Arctic wolf cloning

  Sinogene’s Arctic wolf project used donor cells from a wild female Arctic wolf, oocytes from a female dog, and a beagle surrogate. The company transferred 85 embryos into seven beagles and reported the birth of one Arctic wolf in 2022. The work is presented as a conservation-related application of animal cloning rather than as a conventional consumer product.

• Large-animal biotechnology · 2023

  Horse cloning

  Sinogene began horse-cloning work in 2023. It reported cloning a male horse using skin cells from a horse born in 1995. The available material does not identify a commercial product name, customer, pricing structure, or the broader scope of the equine program.

• 2023

  Enter horse cloningProduct launch

  Background

  Sinogene extended its documented animal-cloning work beyond companion animals and canids.

  Action taken

  The company began horse-cloning activities and reported producing a male horse from preserved skin cells.

  Aftermath

  The move broadened the range of species associated with Sinogene’s biotechnology work, but detailed commercial and scientific results are not available in the cited material.

  Source

• 2022

  Expand cloning work into endangered-animal conservationStrategy

  Background

  After developing commercial companion-animal cloning capabilities, Sinogene pursued conservation-oriented work involving the cloning of a wild Arctic wolf and collaboration with Beijing Wildlife Park.

  Action taken

  The company reported the birth of a cloned Arctic wolf and partnered with Beijing Wildlife Park on endangered-animal breeding and protection efforts.

  Aftermath

  The activities increased Sinogene’s visibility as an animal-conservation biotechnology company, although the available sources do not document long-term program outcomes.

  Source

• 2023

  Sinogene begins horse-cloning activities[1]Sinogene Biotechnologyen.wikipedia.org

  Product launch · Product generation

  Sinogene started horse-cloning work and reported cloning a male horse using skin cells from a horse born in 1995.

• 2022

  Sinogene reports first successful cloning of a wild Arctic wolf[1]Sinogene Biotechnologyen.wikipedia.org

  Product launch · Other

  Sinogene reported the birth of an Arctic wolf produced through a cloning process using cells from a wild female Arctic wolf, dog oocytes, and a beagle surrogate. The company transferred 85 embryos into seven beagles and one Arctic wolf was born.

• 2022

  Sinogene partners with Beijing Wildlife Park on endangered-animal breeding[1]Sinogene Biotechnologyen.wikipedia.org

  Other

  Sinogene and Beijing Wildlife Park began collaborating on approaches intended to improve the breeding and protection of endangered animals.

1. 1Sinogene Biotechnologyen.wikipedia.org
2. 2Sinogene Biotechnology official websitesinogene.org